Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Human Derived Anti-BCMA CAR-T for Relapsed/Refractory Multiple Myeloma
NCT05302648Phase 1Active, not recruiting
- Sponsor
- Shanghai HRAIN Biotechnology
- Start
- Feb 2022
- Primary completion
- Dec 2024
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-BCMA CAR-T in multiple myeloma (MM), sponsored by Shanghai HRAIN Biotechnology. Primary endpoint: Dose Limited Toxicity at 28 days. Started Feb 2022; status: active, not recruiting.
02
Drugs
anti-BCMA CAR-T
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05302648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05302648.